Long-term Efficacy, Safety, and Immunogenicity of Biosimilar Infliximab After One Year in a Prospective Nationwide Cohort-Reference-Cited by-同舟云学术

Long-term Efficacy, Safety, and Immunogenicity of Biosimilar Infliximab After One Year in a Prospective Nationwide Cohort

Published:2017-11 Issue:11 Volume:23 Page:1908-1915
ISSN:1078-0998
Container-title:Inflammatory Bowel Diseases
language:en
Short-container-title:Inflammatory Bowel Diseases

Author:

Gonczi Lorant,Gecse Krisztina B.,Vegh Zsuzsanna,Kurti Zsuzsanna,Rutka Mariann,Farkas Klaudia,Golovics Petra A.,Lovasz Barbara D.,Banai Janos,Bene Laszlo,Gasztonyi Bea,Kristof Tunde,Lakatos Laszlo,Miheller Pal,Nagy Ferenc,Palatka Karoly,Papp Maria,Patai Arpad,Salamon Agnes,Szamosi Tamas,Szepes Zoltan,Toth Gabor T.,Vincze Aron,Szalay Balazs,Molnar Tamas,Lakatos Peter L.

Publisher

Oxford University Press (OUP)

Subject

Gastroenterology,Immunology and Allergy

Reference25 articles.

1. A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study

2. A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study

3. Efficacy and safety of CT-P13, a biosimilar of infliximab, in patients with inflammatory bowel disease: A retrospective multicenter study

5. Efficacy and Safety of the Biosimilar Infliximab CT-P13 Treatment in Inflammatory Bowel Diseases: A Prospective, Multicentre, Nationwide Cohort

Cited by 48 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical experience of using biosimilars in Crohn’s disease and their effectiveness;Expert Opinion on Biological Therapy;2024-09-13

2. Comparative effectiveness and drug survival of biosimilar infliximab CPT-13 vs. reference infliximab in inflammatory bowel disease: A retrospective cohort study;Gastroenterología y Hepatología (English Edition);2024-06

3. Subcutaneous Infliximab (CT-P13 SC) as Maintenance Therapy for Inflammatory Bowel Disease: Two Randomized Phase 3 Trials (LIBERTY);Gastroenterology;2024-05

4. Best Practice for Therapeutic Drug Monitoring of Infliximab: Position Statement from the International Association of Therapeutic Drug Monitoring and Clinical Toxicology;Therapeutic Drug Monitoring;2024-04-17

5. Long-term effectiveness and safety of infliximab-biosimilar: A multicenter Phoenix retrospective cohort study;PLOS ONE;2023-09-12